Clinical Correlation of Transcription Factor SOX3 in Cancer: Unveiling Its Role in Tumorigenesis.
Helen Lima Del PuertoAna Paula G S MirandaDinah QutobEnio FerreiraFelipe H S SilvaBruna M LimaBarbara A CarvalhoBruna Roque-SouzaEduardo GutseitDiego C CastroEmanuele T PozzoliniNayara O DuarteThacyana B G LopesDaiana Y O TabordaStella M QuirinoAhmed ElgerbiJohn S ChoyAdam UnderwoodPublished in: Genes (2024)
Members of the SOX (SRY-related HMG box) family of transcription factors are crucial for embryonic development and cell fate determination. This review investigates the role of SOX3 in cancer, as aberrations in SOX3 expression have been implicated in several cancers, including osteosarcoma, breast, esophageal, endometrial, ovarian, gastric, hepatocellular carcinomas, glioblastoma, and leukemia. These dysregulations modulate key cancer outcomes such as apoptosis, epithelial-mesenchymal transition (EMT), invasion, migration, cell cycle, and proliferation, contributing to cancer development. SOX3 exhibits varied expression patterns correlated with clinicopathological parameters in diverse tumor types. This review aims to elucidate the nuanced role of SOX3 in tumorigenesis, correlating its expression with clinical and pathological characteristics in cancer patients and cellular modelsBy providing a comprehensive exploration of SOX3 involvement in cancer, this review underscores the multifaceted role of SOX3 across distinct tumor types. The complexity uncovered in SOX3 function emphasizes the need for further research to unravel its full potential in cancer therapeutics.
Keyphrases
- transcription factor
- papillary thyroid
- stem cells
- epithelial mesenchymal transition
- squamous cell
- cell cycle
- dna binding
- poor prognosis
- signaling pathway
- type diabetes
- lymph node metastasis
- oxidative stress
- cell death
- genome wide identification
- risk assessment
- adipose tissue
- transforming growth factor
- high grade
- drug induced